Clinical Trial Update: Multiorgan Metabolic Imaging Response Assessment of Abemaciclib [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating multiorgan metabolic imaging response assessment of abemaciclib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Endometrial Cancer
• Esophageal Adenocarcinoma
• Esophageal Squamous Cell Carcinoma
• Urothelial Bladder Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Esophageal Adenocarcinoma, Esophagus SCC | Phase 2 | Status: COMPLETED